Chemotherapy and immunotherapy of malignant mesothelioma
Chemotherapy and immunotherapy of malignant mesothelioma is a topic covered in the Evidence-Based Medicine Guidelines.
To view the entire topic, please sign in or purchase a subscription.
Evidence Central is an integrated web and mobile solution that helps clinicians quickly answer etiology, diagnosis, treatment, and prognosis questions using the latest evidence-based research. Explore these free sample topics:
Citation
"Chemotherapy and Immunotherapy of Malignant Mesothelioma." Evidence-Based Medicine Guidelines, Duodecim Medical Publications Limited, 2019. Evidence Central, evidence.unboundmedicine.com/evidence/view/EBMG/455327/all/Chemotherapy_and_immunotherapy_of_malignant_mesothelioma.
Chemotherapy and immunotherapy of malignant mesothelioma. Evidence-Based Medicine Guidelines. Duodecim Medical Publications Limited; 2019. https://evidence.unboundmedicine.com/evidence/view/EBMG/455327/all/Chemotherapy_and_immunotherapy_of_malignant_mesothelioma. Accessed October 14, 2019.
Chemotherapy and immunotherapy of malignant mesothelioma. (2019). In Evidence-Based Medicine Guidelines. Available from https://evidence.unboundmedicine.com/evidence/view/EBMG/455327/all/Chemotherapy_and_immunotherapy_of_malignant_mesothelioma
Chemotherapy and Immunotherapy of Malignant Mesothelioma [Internet]. In: Evidence-Based Medicine Guidelines. Duodecim Medical Publications Limited; 2019. [cited 2019 October 14]. Available from: https://evidence.unboundmedicine.com/evidence/view/EBMG/455327/all/Chemotherapy_and_immunotherapy_of_malignant_mesothelioma.
* Article titles in AMA citation format should be in sentence-case
TY - ELEC
T1 - Chemotherapy and immunotherapy of malignant mesothelioma
ID - 455327
BT - Evidence-Based Medicine Guidelines
UR - https://evidence.unboundmedicine.com/evidence/view/EBMG/455327/all/Chemotherapy_and_immunotherapy_of_malignant_mesothelioma
PB - Duodecim Medical Publications Limited
DB - Evidence Central
DP - Unbound Medicine
ER -